TPST-3003 / Tempest Therap - LARVOL DELTA

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 (GlobeNewswire) - "Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected near term)...The Proposed Transaction will expand and further diversify Tempest’s existing clinical-stage pipeline, with the acquisition of the first clinical-stage CD19/BCMA parallel structured dual-CAR T specifically designed to target patients with extramedullary disease (EMD), which we are referring to as TPST-2003...Tempest plans to pursue business development discussions or an additional financing to advance the pivotal development of amezalpat (TPST-1120) in first-line liver cancer ('HCC')....Plan to continue the development of additional new preclinical and research-stage pipeline programs: TPST-2206: dual-targeting CD70/CD70 CAR-T for renal cell carcinoma; TPST-3003: allogeneic dual-targeting CD19/BCMA; TPST-3206: allogeneic dual-targeting CD70/CD70."

M&A • Genetic Disorders • Hepatocellular Cancer • Multiple Myeloma • Renal Cell Carcinoma • Systemic Lupus Erythematosus